here.

When he later returned home, Anton thought about the collectors words. He didn’t know what to do. He was walking from one side of the room to another until heard gunshots.

Something happened there.

Either the guards killed the collector or he killed them and now he is coming after him and his movie.Strategies and challenges for the next generation of antibody-drug conjugates.
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody. Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs. In this Review, we discuss strategies to select the best target antigens